1. Home
  2. PLCE vs MGNX Comparison

PLCE vs MGNX Comparison

Compare PLCE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Children's Place Inc. (The)

PLCE

Children's Place Inc. (The)

HOLD

Current Price

$4.25

Market Cap

100.2M

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.73

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLCE
MGNX
Founded
1969
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.2M
115.8M
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
PLCE
MGNX
Price
$4.25
$1.73
Analyst Decision
Hold
Hold
Analyst Count
1
5
Target Price
$4.50
$3.20
AVG Volume (30 Days)
218.9K
546.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
63.35
N/A
EPS
N/A
N/A
Revenue
N/A
$149,962,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
155.26
52 Week Low
$3.66
$0.99
52 Week High
$9.56
$2.63

Technical Indicators

Market Signals
Indicator
PLCE
MGNX
Relative Strength Index (RSI) 45.73 42.87
Support Level $3.80 $1.57
Resistance Level $4.88 $1.70
Average True Range (ATR) 0.25 0.07
MACD 0.06 -0.01
Stochastic Oscillator 44.71 22.68

Price Performance

Historical Comparison
PLCE
MGNX

About PLCE Children's Place Inc. (The)

Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: